Product Description
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Histogen
Company Location: San Diego CA 92121
Company CEO: Steven J. Mento
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cholestasis|Hepatocellular Carcinoma|Hypertension, Portal|Liver Cirrhosis|Hepatitis|Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Type 1 Diabetes|Liver Transplant|Hepatitis C, Chronic|Hepatitis A|Liver Diseases, Alcoholic|Hepatitis, Chronic|End Stage Liver Disease|Acute-On-Chronic Liver Failure|Hepatic Insufficiency|Liver Failure, Acute
Phase 1: COVID-19|Intestinal Diseases|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EMR-COV-PR001 | P1 |
Terminated |
COVID-19 |
2021-05-28 |
69% |
| ENCORE-LF | P2 |
Unknown status |
Liver Cirrhosis |
2019-08-01 |
45% |
| CON-EX-0217 | N/A |
Terminated |
Liver Cirrhosis |
2019-07-15 |
|
| NCT02960204 | N/A |
Completed |
Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic|Hypertension, Portal|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2019-04-08 |
|
| 2015-004473-32 | P2 |
Completed |
Hypertension, Portal|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Liver Cirrhosis |
2019-04-08 |
|
| ENCORE-NF | P2 |
Completed |
Liver Cirrhosis|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Fatty Liver, Alcoholic |
2019-01-29 |
33% |
| 2015-004336-35 | P2 |
Completed |
Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2019-01-29 |
|
| ENCORE-PH | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Hypertension, Portal|Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic |
2018-10-02 |
44% |
| IDN-6556-14 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Hypertension, Portal |
2018-10-02 |
|
| POLT-HCV-SVR | P2 |
Completed |
Liver Cirrhosis |
2018-02-15 |
|
| Pro00024049 | P2 |
Completed |
Type 1 Diabetes |
2016-06-01 |
|
| LC | P2 |
Completed |
Liver Cirrhosis |
2016-01-01 |
|
| AH | P2 |
Terminated |
Hepatitis, Alcoholic|Hepatitis A |
2015-08-01 |
|
| PH | P2 |
Completed |
Hypertension, Portal|Liver Cirrhosis |
2015-05-01 |
|
| NAFLD | P2 |
Completed |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis |
2015-03-01 |
|
| 2012-004245-33 | N/A |
Completed |
Acute-On-Chronic Liver Failure|Liver Failure, Acute |
2015-01-29 |
|
| IDN-6556-02 | P2 |
Terminated |
Acute-On-Chronic Liver Failure|Hepatitis, Alcoholic|Liver Cirrhosis, Alcoholic|End Stage Liver Disease|Hepatic Insufficiency|Hepatitis, Chronic|Liver Failure, Acute |
2015-01-01 |
|
| IDN-6556-08 | P1 |
Completed |
Intestinal Diseases |
2014-07-01 |
|
| IDN-6556-05 | P1 |
Completed |
Kidney Diseases |
2014-04-01 |
|
| CL-000006556-PRO-0006 | P2 |
Completed |
Cholestasis|Liver Transplant|Hepatocellular Carcinoma|Hepatitis |
2006-01-01 |
|
| CL-000006556-PRO-0007 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2005-10-01 |